PF-Atlas › Clinical Trials › NCT06758947

Use of Selective JAK Inhibitor in ILD and Skin Tightness of Systemic Sclerosis Versus MMF

Upadacitinib 15 MG · Phase 3

Registry ID
NCT06758947
Phase
Phase 3
Status
Completed
Drug / intervention
Upadacitinib 15 MG
Sponsor
Assiut University
Start
2023-01-15

About this trial

Upadacitinib 15 MG is evaluated in NCT06758947, a Phase 3 idiopathic pulmonary fibrosis study sponsored by Assiut University. Current status: Completed.

View NCT06758947 on ClinicalTrials.gov →

Explore related

All Upadacitinib 15 MG trialsAll IPF trials
Medical disclaimer. This page summarizes public trial data for NCT06758947 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.